Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 11,895 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment Effectiveness Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pimecrolimus Cream for Oral Lichen Planus

NCT00297037
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Pimecrolimus 1% cream
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

NCT02380612
View directory record Official record
Conditions
Burns
Interventions
ReCell Treatment, Skin Graft
Device · Procedure
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Not applicable Interventional

Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP

NCT00901771
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Provent
Device
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 30, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

NCT02701634
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
ENTO, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

SUPER Study (Substance Use and PTSD Treatment Effectiveness Research Study)

NCT00265564
View directory record Official record
Conditions
Substance Use Disorders, Posttraumatic Stress Disorder
Interventions
Modified Seeking Safety integrated into std outpatient SUD care, Standard outpatient SUD care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 30, 2026, 7:01 AM EDT
Enrolling by invitation No phase listed Observational

Karma Ambispective Study

NCT07207187
View directory record Official record
Conditions
Subjects Treated With Karma Fixation System as Part of Their Spine Surgery
Interventions
Not listed
Lead sponsor
Spinal Elements
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Gilbert, Arizona • Jacksonville, Florida • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Not applicable Interventional

Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

NCT05592548
View directory record Official record
Conditions
Rosacea, Papulopustular
Interventions
cold atmospheric plasma
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 30, 2026, 7:01 AM EDT
Completed No phase listed Observational

Efficacy of Conversation Training Therapy (CTT)

NCT02441348
View directory record Official record
Conditions
Voice Disorders
Interventions
Conversation Training Therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 30, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of AMG 827 in Subjects With RA

NCT01059448
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AMG 827
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
View directory record Official record
Conditions
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions
I-131-1095, Enzalutamide
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects

NCT02015390
View directory record Official record
Conditions
Segmental Long Bone Defects
Interventions
Autogenous RIA bone grafting, Allogeneic bone grafting
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Ramelteon in Healthy Subjects

NCT00671190
View directory record Official record
Conditions
Sleep Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
13
States / cities
Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008410
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

DL6049 vs CosmoPlast in the Treatment of Nasolabial Fold Wrinkles

NCT00444210
View directory record Official record
Conditions
Nasolabial Fold Wrinkles
Interventions
DL6049 (injectable poly-L-lactic acid)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

NCT00174733
View directory record Official record
Conditions
Asthma
Interventions
Ciclesonide (XRP1526)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

NCT00097825
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years to 85 Years · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Walnut Creek, California • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 30, 2026, 7:01 AM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 30, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 7:01 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation

NCT01955616
View directory record Official record
Conditions
Parkinson's Disease
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Los Angeles, California • Englewood, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 30, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 30, 2026, 7:01 AM EDT